GE Healthcare Inaugurates Open-Access Lab at Alderley Park

October 24, 2019
Pharmaceutical Technology Editors

GE Healthcare has announced the inauguration of an open-access lab at the Mereside Campus of Alderley Park in the United Kingdom, which will be used to support acceleration of biotech, health, and life-sciences research.

GE Healthcare has announced the inauguration of an open-access lab at the Mereside Campus of Alderley Park in the United Kingdom, which will be used to support acceleration of biotech, health, and life-sciences research.

According to an Oct. 23, 2019 press release, the new lab will feature advanced protein and cell analysis technologies to support small and medium-sized enterprises (SMEs) from early stage R&D to process development through to manufacturing. Additionally, it is hoped that valuable insights into the challenges faced by SMEs will be gained from the experiences with the open-access lab, allowing for the development of solutions that could benefit the whole life-sciences community in the UK.

“We’re thrilled to be launching this facility which will help accelerate our customers’ research and discovery aims,” said Kath Mackay, managing director, Alderley Park, in the press release. “The new GE laboratory is an excellent addition to the highly specialized scientific services offered at the Park and complements the existing oncology, analytical, and open access services.”

Conor McKechnie, chief marketing officer, GE Healthcare Life Sciences, added, “The start-up community at Alderley Park has the creativity, vision, and scientific expertise to help transform medicine. Providing them access to our technologies and services is a natural part of our mission to accelerate and advance biotherapeutics.”

“GE Healthcare Life Sciences is an important partner for the BioIndustry Association (BIA) and our community,” stated Steve Bates OBE, chief executive of the BIA. “This new lab will give our members early access and training for all the tools they need for drug discovery, protein science, and bioprocessing research.”

Source: GE Healthcare